DRG Market Assessment reports

Treatment of CSU and CIndU is dominated by oral medications, including approved therapies such as first- and second-generation antihistamines and a range of off-label options (e.g.,…

With a drug-treated population of more than 3.3 million in the United States, France, Germany, and the United Kingdom, the moderate to severe psoriasis therapy market has been a lucrative space for…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the European countries (Austria, Belgium, Czech Republic…

Clarivate Epidemiology’s coverage of obsessive-compulsive disorder (OCD) comprises epidemiological estimates of key patient populations in the major mature pharmaceutical markets (the United…

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate Epidemiology’s coverage of irritable bowel syndrome (IBS) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report the prevalence of IBS for…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key irritable bowel syndrome patient populations, covering 171…

Clarivate Epidemiology’s coverage of irritable bowel syndrome comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report prevalence of irritable bowel…

Clarivate’s Extrapolated Worldwide Coverage is the first and only evidence-based data set of epidemiological forecasts for key cystic fibrosis patient populations covering 171 countries and more…

TNF-alpha inhibitors (Johnson & Johnson Innovative Medicine ’s Remicade, AbbVie’s Humira), a CAM inhibitor (Takeda’s Entyvio), a JAK inhibitor (Pfizer’s Xeljanz), and an IL-12/23 inhibitor…

Clarivate’s Epidemiology’s coverage of cystic fibrosis (CF) comprises epidemiological estimates of key patient populations in 45 countries worldwide. We report both the incidence and prevalence…

Primary biliary cholangitis (PBC) is a rare autoimmune liver disease characterized by inflammation, progressive damage, and destruction of the interlobular bile ducts, followed by cholestasis,…